Publications
The Promise and Peril of Alzheimer Disease Prevention
Prognostic Value of Blood-Based P-Tau217 Levels for Progression to Cognitive Impairment
Ceperognastat in Alzheimer Disease: Lessons From a Negative Clinical Trial
Hippocampal asymmetry captures non-amyloid-related risk of memory decline and clinical progression
Beyond Binary-The Case for Amyloid Centiloid Quantification
Eligibility of men vs. women in Alzheimer’s trials: Inclusive vs. representative
Scalable markers for early cognitive decline: Plasma p-tau217, subjective cognitive concerns, and digital testing: Results from the A4/LEARN studies
A plasma protein signature for cerebral amyloid angiopathy
Interrupted Time Series Methods for Nonrandom Sampling Study Designs With Known Sampling Weights
Outreach, Recruitment and Engagement Cores of NIA-designated Alzheimer's Disease Research Centers: Current strategies and future directions
Amyloid-related imaging abnormalities (ARIA) in anti-amyloid therapies for Alzheimer's disease: An update from the Alzheimer's Association ARIA workgroup
Amyloid Imaging and APOE Genotype Disclosure and Short-Term Psychological Distress
Cognitive screening biases in a secondary prevention Alzheimer's disease clinical trial
A path to preventing cognitive impairment due to Alzheimer's disease: initiatives beginning in the USA.
Digital memory assessments and plasma pTau217 enable efficient preclinical Alzheimer's trials
Uniform Amyloid Thresholds Across Populations
Disclosing Alzheimer Biomarkers to Motivate Brain Health Behaviors
Blood Tests for Alzheimer Disease—What to Do With the Holy Grail
Impact of learning APOE genotype on cognitively unimpaired adults: a pre-screening cohort study of the Alzheimer’s Prevention Initiative Generation Study 1
Current evidence of randomized clinical trials on hospice-eligible patients with agitation and dementia: A narrative review
Prognostic value of plasma glial fibrillary acidic protein in cognitively unimpaired older adults: Results from the A4 study
Recruitment and retention in a preclinical AD trial: comparisons between academic and non-academic sites
Alzheimer’s Disease Clinical Trial Decision-Making Among Patients with Mild Cognitive Impairment and Their Study Partners
Characterizing the Research Participant Recruitment Funnel for Alzheimer's Secondary Prevention Trials: Results from A National Survey of U.S. Adults.
Modernizing diagnosis of Alzheimer's disease: A review of global trends and Asia-specific perspectives.
Alzheimer's Disease Research Center Down Syndrome Cores: Experience from two sites
Effectiveness of a local recruitment registry in older adults in Southern California.
Five years of the Institute on Methods and Protocols for Advancement of Clinical Trials in ADRD (IMPACT-AD).
It is time to share Alzheimer biomarker results in dementia with Lewy bodies.
Late-life emergence of neuropsychiatric symptoms and risk of cognitive impairment in cognitively unimpaired individuals
Racial and ethnic differences in plasma p-tau217 ratio biomarker eligibility rates in a preclinical AD trial with lecanemab.
Aligning Alzheimer Disease Biology With Care
Understanding participants' attitudes toward research in the CARE registry.
Association of Alzheimer's disease concerns with amyloid burden and lifestyle behaviors in cognitively unimpaired older adults.
The Bad Medicine of Doctored
The science does not yet support regulatory approval of amyloid‐targeting therapies for Alzheimer's disease based solely on biomarker evidence
Increasing representation of Asian American, Native Hawaiian, and Pacific Islander communities in aging, dementia, and caregiving research: An update from the CARE registry
Estimating the optimal cutoff for the IGT-AD Distress subscale adapted for amyloid PET results disclosure.
Virtual Data Collection Strategies in Research on Alzheimer's Disease and Related Dementias (ADRD)
Pharmacokinetic and pharmacodynamic assessment of oral nicotinamide in the NEAT clinical trial for early Alzheimer's disease
Effects of intensive lifestyle changes on the progression of mild cognitive impairment or early dementia due to Alzheimer's disease: the need for rigor.
Disclosure of elevated amyloid status is not associated with long-term suicidality in a preclinical AD trial
Research Attitudes Questionnaire scores and retention in a recruitment registry.
Impact of study partner replacement in a mild cognitive impairment clinical trial
Phase 2A Proof-of-Concept Double-Blind, Randomized, Placebo-Controlled Trial of Nicotinamide in Early Alzheimer Disease
Impacts of informant replacement in two industry-sponsored Alzheimer's disease clinical trials
Views and Perceptions of Amyloid Imaging in a Preclinical Alzheimer's Disease Trial
Alzheimer's disease biomarkers and the tyranny of treatment
Community recruitment of underrepresented populations to the AHEAD 3-45 preclinical AD trial using novel partnerships with nursing and community-based organizations: Lessons and outcomes
The utility of recruitment incentives in early Alzheimer's disease trials.
Centers for Medicare and Medicaid Services Coverage of Amyloid PET
The AlzMatch Pilot Study - Feasibility of Remote Blood Collection of Plasma Biomarkers for Preclinical Alzheimer's Disease Trials
Estimating Socio-Economic Status for Alzheimer’s Disease Trials
Comparing research attitudes in Down syndrome and non-Down syndrome research decision-makers
Apolipoprotein E Genetic Testing in a New Age of Alzheimer Disease Clinical Practice.
Pre-Randomization Predictors of Study Discontinuation in a Preclinical Alzheimer’s Disease Randomized Controlled Trial.
Longitudinal Trajectories of the Cognitive Function Index in the A4 Study
Amyloid and Tau Prediction of Cognitive and Functional Decline in Unimpaired Older Individuals: Longitudinal Data from the A4 and LEARN Studies.
The Collaborative Approach for Asian Americans and Pacific Islanders Research Dominantly Inherited Alzheimer Network Trials Unit (DIAN-TU): Trial Satisfaction and Attitudes towards Future Clinical Trials.
Racial and ethnic differences in plasma biomarker eligibility for a preclinical Alzheimer's disease trial
Immediate Reactions to Alzheimer Biomarker Disclosure in Cognitively Unimpaired Individuals in a Global Truncated Randomized Trial
Study Partner Type and Adverse Event Reporting in Mild-to-Moderate Alzheimer's Disease Clinical Trials
A Pragmatic, Investigator-Driven Process for Disclosure of Amyloid PET Scan Results to ADNI-4 Research Participants.
Alzheimer's Disease Biomarker Decision-Making among Patients with Mild Cognitive Impairment and Their Care Partners.
Post-disclosure distress among racial and ethnic groups in a preclinical AD trial.
Alzheimer’s Disease Cooperative Study. Study Partner Type and Adverse Event Reporting in Mild-to-Moderate Alzheimer's Disease Clinical Trials.
Vietnamese American Perspectives on Engagement in an Aging-Focused Research Registry.
Eligibility Rates among Racially and Ethnically Diverse US Participants in Phase 2 and Phase 3 Placebo-Controlled, Double-Blind, Randomized Trials of Lecanemab and Elenbecestat in Early Alzheimer Disease.
Examining Utilization of Formal Supports and Related Impacts on Overall Well-Being Among East Asian American Family Caregivers of Persons With Dementia: A Mixed-Methods Study.
Remaining Questions in a Brave New World of Alzheimer's Disease Care.
Biomarker disclosure protocols in prodromal Alzheimer's disease clinical trials
The Collaborative Approach for Asian Americans and Pacific Islanders Research and Education (CARE): A recruitment registry for Alzheimer's disease and related dementias, aging, and caregiver-related research.
Economic hardships of Korean American family caregivers of persons with dementia: a mixed-methods study.
US Adults' Likelihood to Participate in Dementia Prevention Drug Trials: Results from the National Poll on Healthy Aging.
Testing for Alzheimer Disease Biomarkers and Disclosing Results Across the Disease Continuum.
Recruitment across two decades of NIH-funded Alzheimer's disease clinical trials.
Centralizing prescreening data collection to inform data-driven approaches to clinical trial recruitment.
Asian Americans' and Pacific Islanders' preferences in recruitment strategies and messaging for participation in the CARE registry: A discrete choice experiment.
Retention of Study Partners in Longitudinal Studies of Alzheimer Disease.
Alzheimer’s Disease Neuroimaging Initiative. Frameworks for estimating causal effects in observational settings: comparing confounder adjustment and instrumental variables.
Recruitment across two decades of NIH-funded Alzheimer's disease clinical trials.Cohort Effects in Alzheimer's Disease Trials: An Empirical Assessment Utilizing Data from the Alzheimer's Disease Cooperative Study.
Advisory Group on Risk Evidence Education in Dementia (AGREED). Biomarker disclosure protocols in prodromal Alzheimer's disease clinical trials.
A4 Study Team. Trial of Solanezumab in Preclinical Alzheimer's Disease.
Brain Health Registry Study Partner Portal: Novel infrastructure for digital, dyadic data collection.
Estimating attrition in mild-to-moderate Alzheimer's disease and mild cognitive impairment clinical trials.
Retention of American Indian and Alaska Native participants in the National Alzheimer's Coordinating Center Uniform Data Set.
Effects of informant replacement in Alzheimer's disease clinical trials.
Diversifying Recruitment Registries: Considering Neighborhood Health Metrics.
A Blood Test for Alzheimer's Disease: It's about Time or Not Ready for Prime Time?
Moving beyond disclosure: Stages of care in preclinical Alzheimer's disease biomarker testing.
You've Got a Friend in Me: How Cognitively Unimpaired Older Adults Select a Study Partner to Participate with Them in Alzheimer's Disease Research.
Retaining Participants in Longitudinal Studies of Alzheimer's Disease.
Dyadic Enrollment in a Phase 3 Mild Cognitive Impairment Clinical Trial.
Strategies Associated with Retaining Participants in the Longitudinal National Alzheimer's Coordinating Center Uniform Data Set Study.
Anxiety and Depressive Symptoms and Cortical Amyloid-β Burden in Cognitively Unimpaired Older Adults.
Perceptions of Research Burden and Retention Among Participants in ADRC Cohorts.
Tackling a Major Deficiency of Diversity in Alzheimer's Disease Therapeutic Trials: An CTAD Task Force Report.
The Advisory Group on Risk Evidence Education for Dementia: Multidisciplinary and Open to All.
What Should the Goals Be for Diverse Recruitment in Alzheimer Clinical Trials?
Preclinical Alzheimer Disease and the Electronic Health Record: Balancing Confidentiality and Care.
Effect of Aducanumab Approval on Willingness to Participate in Preclinical Alzheimer's Disease Trials.
Alzheimer's Disease Clinical Trial Research Adaptation Following COVID-19 Pandemic Onset: National Sample of Alzheimer's Clinical Trial Consortium Sites.
Research attitudes in families of individuals with Down syndrome: importance for clinical trials.
The approval of Aduhelm risks eroding public trust in research and the FDA.
Reasons for undergoing amyloid imaging among cognitively unimpaired older adults.
Asian Americans and Pacific Islanders’ Perspectives on Participating in the CARE Recruitment Research Registry for Alzheimer’s Disease and Related Dementias, Aging, and Caregiving Research.
Implications of FDA approval of a first disease-modifying therapy for a neurodegenerative disease on the design of subsequent clinical trials.
The Institute on Methods and Protocol for Advancement of Clinical Trials in ADRD (IMPACT-AD): A novel clinical trials training program.
Recruitment and Retention of Participant and Study Partner Dyads in Two Multinational Alzheimer’s Disease Registration Trials.
Research attitudes questionnaire scores predict Alzheimer’s disease clinical trial dropout.
Disparities by race and ethnicity among adults recruited for a preclinical Alzheimer’s disease trial.
Using Direct-to-Consumer Genetic Testing Results to Accelerate Alzheimer’s Disease Clinical Trial Recruitment.
Recruitment into the Alzheimer Prevention Trials (APT) Webstudy for a Trial-Ready Cohort for Preclinical and Prodromal Alzheimer’s Disease (TRC-PAD)
Education and Message Framing Increase Willingness to Undergo Research Lumbar Puncture: A Randomized Controlled Trial.
Short-term Psychological Outcomes of Disclosing Amyloid Imaging Results to Research Participants Who Do Not Have Cognitive Impairment.